Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central anxious technique, conolidine modulates alternate molecular targets. A Science Developments study found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://alexanderw074zpf0.wikitelevisions.com/user